Back to Newsroom
Back to Newsroom

Solo-Dex(R) Fascile(R) Nerve Block Catheter Has Been Designated Safe for the Magnetic Resonance (MR) Environment

Thursday, August 25, 2022 8:30 AM
Solo-Dex, Inc.

WOLF CREEK, MT / ACCESSWIRE / August 25, 2022 / Solo-Dex Fascile Nerve Block Catheter has been designated save for use in a magnetic resonance environment. The "MR" designation means that patients no longer need to interrupt their pain management to obtain MR imaging. In addition, patients no longer need to undergo repeat placement of a nerve block catheter following an MRI imaging. Solo-Dex green "MR" designation will improve patient satisfaction, reduce costs and drive efficiency in a hospital and in the ambulatory surgical center.

Solo-Dex proprietary catheters lead the industry and are designed for single operator control of placement visualization, catheter and medication. Solo-Dex catheter technology enhances control, reduces complexity and unlocks the potential for increased patient satisfaction. Solo-Dex's goal is to become the new standard of care for acute pain management before, during and for days after surgery.

"The MR designation for our catheters is one more step toward our mission to lead pain management with the fastest, simplest and most reliable acute pain management that stays in place before, during and for days of at-home recovery. Precision control over the amount, timing and type of medication offers a very high level of pain control without the risks of oral opioid therapy. Now, Solo-Dex acute pain management can continue without interruption or extraction and replacement," said Steven Eror, CEO of Solo-Dex.

About Solo-Dex, Inc.

Solo-Dex is a private MedTech company focused improvement and expansion of regional anesthesia for acute pain management before, during and for days after surgery. Beyond safe and effective, proprietary Solo-Dex nerve block products are developed, manufactured and commercialized to be fast, simple and reliable as well as the easiest catheter to use for the management of acute pain. Solo-Dex products have been cleared for use by the US FDA. For more information, log on to

Steve Eror, CEO
[email protected]

SOURCE: Solo-Dex, Inc.

Product Announcements
Back to newsroom
Back to Newsroom